[{"id":"7737d144-a404-4582-aab1-5735a517fdd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03206047","created_at":"2021-01-18T15:48:08.496Z","updated_at":"2024-07-02T16:35:11.758Z","phase":"Phase 1/2","brief_title":"Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT03206047","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CTAG1B","pipe":" | ","alterations":" PD-L1 expression • CTAG1B expression","tags":["PD-L1 • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Hiltonol (poly-ICLC) • guadecitabine (SGI-110) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 11/08/2017","start_date":" 11/08/2017","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-04-03"},{"id":"1cfc9dae-087d-4a45-888a-feae0e1a43ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT02166905","created_at":"2021-01-18T10:05:33.255Z","updated_at":"2024-07-02T16:35:54.811Z","phase":"Phase 1/2","brief_title":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission","source_id_and_acronym":"NCT02166905","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CTAG1B • CD4 • CTAG2","pipe":"","alterations":" ","tags":["CTAG1B • CD4 • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e epacadostat (INCB024360) • Hiltonol (poly-ICLC) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 10/10/2014","start_date":" 10/10/2014","primary_txt":" Primary completion: 08/20/2020","primary_completion_date":" 08/20/2020","study_txt":" Completion: 08/20/2020","study_completion_date":" 08/20/2020","last_update_posted":"2023-02-24"},{"id":"b8b377f8-f74b-4e8e-8bac-28bf811e0fc5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02129075","created_at":"2021-01-18T09:52:16.035Z","updated_at":"2024-07-02T16:36:20.676Z","phase":"Phase 2","brief_title":"A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma","source_id_and_acronym":"NCT02129075","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CTAG1B • CD4 • PRAME","pipe":" | ","alterations":" CTAG1B expression","tags":["CTAG1B • CD4 • PRAME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC) • Mobista (CDX-301) • Neo Vax (NEO-PV-01) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 04/09/2014","start_date":" 04/09/2014","primary_txt":" Primary completion: 03/28/2016","primary_completion_date":" 03/28/2016","study_txt":" Completion: 05/18/2018","study_completion_date":" 05/18/2018","last_update_posted":"2021-11-16"},{"id":"6e060b6a-aecb-4f0c-b730-57d52b351ad4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03358719","created_at":"2021-01-19T15:11:58.492Z","updated_at":"2024-07-02T16:36:23.457Z","phase":"Phase 1","brief_title":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia","source_id_and_acronym":"NCT03358719","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CTAG1B","pipe":"","alterations":" ","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • azacitidine • decitabine • Hiltonol (poly-ICLC) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 03/27/2018","start_date":" 03/27/2018","primary_txt":" Primary completion: 02/27/2020","primary_completion_date":" 02/27/2020","study_txt":" Completion: 08/25/2021","study_completion_date":" 08/25/2021","last_update_posted":"2021-10-05"},{"id":"6f59b423-d252-4549-aefd-b391ba3f1d88","acronym":"","url":"https://clinicaltrials.gov/study/NCT02495636","created_at":"2021-01-18T12:02:02.112Z","updated_at":"2024-07-02T16:37:20.748Z","phase":"Phase 2","brief_title":"Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02495636","lead_sponsor":"Yale University","biomarkers":" ALK • CTAG1B","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • CTAG1B expression • EGFR rearrangement","tags":["ALK • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • CTAG1B expression • EGFR rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 07/01/2017","primary_completion_date":" 07/01/2017","study_txt":" Completion: 07/01/2017","study_completion_date":" 07/01/2017","last_update_posted":"2017-06-22"},{"id":"76d6d652-9886-49e6-a14f-4c2aee759843","acronym":"","url":"https://clinicaltrials.gov/study/NCT02661100","created_at":"2021-01-19T11:37:09.807Z","updated_at":"2024-07-02T16:37:27.223Z","phase":"Phase 1/2","brief_title":"A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients","source_id_and_acronym":"NCT02661100","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" CTAG1B","pipe":" | ","alterations":" CTAG1B expression","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Hiltonol (poly-ICLC) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2017","start_date":" 01/01/2017","primary_txt":" Primary completion: 07/01/2018","primary_completion_date":" 07/01/2018","study_txt":" Completion: 07/01/2018","study_completion_date":" 07/01/2018","last_update_posted":"2016-12-07"},{"id":"5a7da577-449f-48ff-aecb-76b7d1bdc934","acronym":"","url":"https://clinicaltrials.gov/study/NCT01522820","created_at":"2021-01-18T06:24:54.609Z","updated_at":"2024-07-02T16:37:28.702Z","phase":"Phase 1","brief_title":"Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors","source_id_and_acronym":"NCT01522820","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" ER • CTAG1B • CTAG2","pipe":" | ","alterations":" ER positive • ER negative","tags":["ER • CTAG1B • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • sirolimus • rasdegafusp alfa (CDX-1401)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 03/01/2012","start_date":" 03/01/2012","primary_txt":" Primary completion: 07/01/2016","primary_completion_date":" 07/01/2016","study_txt":" Completion: 07/01/2016","study_completion_date":" 07/01/2016","last_update_posted":"2016-10-04"},{"id":"486a7268-0c1e-40c7-9938-60bd7f99084b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00948961","created_at":"2021-02-16T02:52:13.619Z","updated_at":"2024-07-02T16:37:31.027Z","phase":"Phase 1/2","brief_title":"A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1","source_id_and_acronym":"NCT00948961","lead_sponsor":"Celldex Therapeutics","biomarkers":" CTAG1B","pipe":" | ","alterations":" CTAG1B expression","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 06/01/2012","primary_completion_date":" 06/01/2012","study_txt":" Completion: 02/01/2014","study_completion_date":" 02/01/2014","last_update_posted":"2016-06-27"}]